Condition:  Cluster HeadacheInterventions:  Drug: Botulinum Toxin Type A 25 IU;  Drug: Botulinum Toxin Type A 12.5 IUSponsors:  Norwegian University of Science and Technology;  St. Olavs HospitalRecruiting – verified April 2017 Source: Cluster Headache Clinical TrialsRead More →
Since its discovery, Onabotulinum toxins have been tried for the treatment of various head, neck and face pain syndromes. The end result of controlled clinical trials was that there was not clear evidence for use in many of the common primary and secondary headaches. In chronic migraine, affecting 1-2% of the population, a fixed site and fixed dose treatment approach was shown to be superior to placebo and was approved for use. In this review, evidence for that use and the history leading to it is described.Read More →
The objective of this open single-centre study was to evaluate the efficacy and tolerability of botulinum toxin type-A (BTX-A) as add-on in the prophylactic treatment of cluster headache (CH). Twelve male patients with episodic (n=3) or chronic (n=9) CH, unresponsive to common prophylactic medications, were treated with a cumulative dose of 50 International Units (IU) BTX-A according to a standardised injection scheme into the ipsilateral pericranial muscles.Read More →